FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
   

Newsletter Home

Newsletter Index
Newsletter Issues
Newsletter Fact Sheet
Subscribe to the Newsletter

Index to Drug-Specific Information

MedWatch: The FDA Safety Information and Adverse Event Reporting Program
MedWatch 2008 Safety Alerts
Voluntary Reporting to MedWatch

Adverse Event Reporting System (AERS)

Email Us
Call Us
1-888-INFO-FDA
(1-888-463-6332) or
(301) 827-4570
 
Newsletter Index, Volume 1, 2007-2008
A B C D E F G H I J K L M
N O P Q R S T U V W X Y Z

An index to brand-name drugs, generic drugs and health issues discussed in Drug Safety Newsletter articles. A list of drug safety alerts and communications can be found on the Index to Drug-Specific Information.

Page numbers refer to the print version (PDF).


A
Acute Pancreatitis
Exenatide, 12-14
Adalimumab
Serious Skin Reactions, 18-22
Alimta, 30-32
Amiodarone, 46-48
Aplastic Anemia
Temozolomide, 7-8




B
Byetta, 12-14




C
Carbamazepine
HLA-B*1502, 35-37
Stevens-Johnson Syndrome, 35-37
Toxic Epidermal Necrolysis, 35-37
Carbatrol, 35-37
Cialis, 15-17
Cordarone, 46-48
Cymbalta, 22-24




D
Deferasirox, 8-9
Duloxetine, 22-24




E
Enbrel, 18-22
Equetro, 35-37
Erythema Multiforme
Lenalidomide, 43-46
Etanercept
Serious Skin Reactions, 18-22
Exenatide
Acute Pancreatitis, 12-14
Exjade, 8-9
Extraneal, 49




G
Glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ), 49
Glucose-dye-oxidoreductase (GDO), 49




H
Hearing Loss
PDE-5 Inhibitors, 15-17
Sildenafil, 15-17
Tadalafil, 15-17
Vardenafil, 15-17
HLA-B*1502
Carbamazepine, 35-37
Humira, 18-22
Hypoglycemia
Icodextrin, 49




I
Icodextrin
Extraneal, 49
Infliximab
Serious Skin Reactions, 18-22




L
Lariam, 41-43
Lenalidomide
Serious Skin Reactions, 43-46
Levitra, 15-17




M
Medication Errors, 50-52
Mefloquine Hydrochloride
Pneumonitis, 41-43
Modafinil
Serious Skin Reactions, 5-7




N
Natalizumab
Serious Liver Injury, 33-35




P
Pacerone, 46-48
PDE-5 Inhibitors
Hearing Loss, 15-17
Pemetrexed
Radiation Recall, 30-32
Pharmacogenomics, 24-26
PML (Progressive Multifocal Leukoencephalopathy), 3-5
Pneumonitis
Mefloquine Hydrochloride, 41-43
Progressive Multifocal Leukoencephalopathy (PML), 3-5
Provigil, 5-7




R
Radiation Recall
Pemetrexed, 30-32
Remicade, 18-22
Revatio, 15-17
Revlimid, 43-46
Rhabdomyolysis
Amiodarone, 46-48
Simvastatin, 46-48
Zocor, 46-48
Vytorin, 46-48
Simcor, 46-48
Cordarone, 46-48
Pacerone, 46-48
Rituxan, 3-5
Rituximab
Progressive Multifocal Leukoencephalopathy (PML), 3-5




S
Serious Liver Injury
Natalizumab, 33-35
Serious Skin Reactions
Adalimumab, 18-22
Etanercept, 18-22
Infliximab, 18-22
Lenalidomide, 43-46
Modafinil, 5-7
TNF-α Antagonists, 18-22
Sildenafil
Hearing Loss, 15-17
Simcor, 46-48
Simvastatin, 46-48
Stevens-Johnson Syndrome
Carbamazepine, 35-37
Lenalidomide, 43-46




T
Tadalafil
Hearing Loss, 15-17
Tegretol, 35-37
Temodar, 7-8
Temozolomide
Aplastic Anemia, 7-8
TNF-α Antagonists
Serious Skin Reactions, 18-22
Toxic Epidermal Necrolysis
Carbamazepine, 35-37
Lenalidomide, 43-46
Tysabri, 33-35




V
Vardenafil
Hearing Loss, 15-17
Viagra, 15-17
Vytorin, 46-48




Z
Zocor, 46-48

horizonal rule
   
horizonal rule